Exactech (NASDAQ:EXAC) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Exactech (NASDAQ:EXAC) from a sell rating to a hold rating in a report issued on Tuesday, December 26th.

According to Zacks, “Exactech, Inc. develops, manufactures, markets and distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. Its principal products include its knee and hip replacement systems. Exactech, Inc. is headquartered in Gainesville, Florida. “

Other research analysts have also recently issued research reports about the company. Sidoti cut Exactech from a buy rating to a neutral rating in a research report on Monday, October 23rd. Robert W. Baird reaffirmed a hold rating and set a $49.00 price target on shares of Exactech in a research report on Thursday, December 7th. Gabelli lowered Exactech from a buy rating to a hold rating in a research note on Tuesday, October 24th. Finally, ValuEngine lowered Exactech from a buy rating to a hold rating in a research note on Friday, December 1st. Six analysts have rated the stock with a hold rating, Exactech has a consensus rating of Hold and a consensus target price of $49.00.

Exactech (NASDAQ:EXAC) opened at $50.50 on Tuesday. Exactech has a 1 year low of $23.30 and a 1 year high of $50.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 4.08. The company has a market capitalization of $725.49, a price-to-earnings ratio of 5,050.00, a PEG ratio of 3.65 and a beta of 1.02.

Exactech (NASDAQ:EXAC) last issued its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). Exactech had a net margin of 0.18% and a return on equity of 7.22%. The firm had revenue of $61.40 million for the quarter, compared to analysts’ expectations of $61.78 million. sell-side analysts forecast that Exactech will post 1.29 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company raised its stake in shares of Exactech by 3.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,323 shares of the medical equipment provider’s stock valued at $278,000 after purchasing an additional 289 shares during the period. Teachers Advisors LLC raised its stake in shares of Exactech by 2.7% during the 2nd quarter. Teachers Advisors LLC now owns 21,549 shares of the medical equipment provider’s stock valued at $642,000 after purchasing an additional 568 shares during the period. California Public Employees Retirement System raised its stake in shares of Exactech by 4.5% during the 2nd quarter. California Public Employees Retirement System now owns 23,100 shares of the medical equipment provider’s stock valued at $688,000 after purchasing an additional 1,000 shares during the period. Numeric Investors LLC raised its stake in shares of Exactech by 4.4% during the 2nd quarter. Numeric Investors LLC now owns 30,643 shares of the medical equipment provider’s stock valued at $913,000 after purchasing an additional 1,300 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Exactech by 6.1% in the 2nd quarter. Alliancebernstein L.P. now owns 24,456 shares of the medical equipment provider’s stock worth $729,000 after acquiring an additional 1,400 shares during the last quarter. Institutional investors own 66.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Exactech (NASDAQ:EXAC) Rating Increased to Hold at Zacks Investment Research” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/exactech-exac-upgraded-at-zacks-investment-research.html.

About Exactech

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Get a free copy of the Zacks research report on Exactech (EXAC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply